Dyne Therapeutics (DYN)

• Market cap: $928M
• 1 day: 4.34%
• 5 days: 17.55%
• 1 month: -33.63%
• 3 months: -42.18%
• 6 months: -76.48%
• Year to date: -67.91%
• 1 year: -67.08%
• 5 years: -65.82%
• 10 years: -74.72%
• Sector: Healthcare
• Industry: Biotechnology

About: Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Employees: 191

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

10% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 62

9% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 34

1% less funds holding

Funds holding: 201 [Q3] → 199 (-2) [Q4]

1.91% less ownership

Funds ownership: 111.57% [Q3] → 109.65% (-1.91%) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 7 (-3) [Q4]

35% less capital invested

Capital invested by funds: $4.02B [Q3] → $2.63B (-$1.39B) [Q4]

65% less call options, than puts

Call options by funds: $3.57M | Put options by funds: $10.3M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 108% upside
• Avg. target: $44 432% upside
• High target: $50 512% upside

6 analyst ratings

• positive: 5 83%
• neutral: 1 17%
• negative: 0 0%

JP Morgan Tessa Romero 23% 1-year accuracy 3 / 13 met price target	108% upside $17	Neutral Maintained	21 Mar 2025
HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target	463% upside $46	Buy Reiterated	17 Mar 2025
Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target	512% upside $50	Buy Maintained	17 Mar 2025
BMO Capital Kostas Biliouris 6% 1-year accuracy 1 / 17 met price target	512% upside $50	Outperform Initiated	12 Mar 2025
Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target	512% upside $50	Sector Outperform Initiated	7 Mar 2025